Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose or doses of HM11260C, when
administered once a month under the skin, to improve the control of blood sugar levels in
patients with early-stage type 2 diabetes mellitus (T2DM).